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3If language were liquid
It would be rushing in
Instead here we are
In a silence more eloquent
Than any word could ever be
These words are too solid
They don't move fast enough
To catch the blur in the brain
That flies by and is gone
Gone
Gone
Gone
By Suzanne Vega, 1985
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9ABSTRACT
The abnormal permselectivity within the glomerulus manifests itself as proteinuria. The
molecular mechanisms of proteinuria have remained obscure while knowledge of the
structure and function of the glomerulus has steadily grown in the last forty years. These data
have been largely obtained utilizing experimental animal models. After discovery of the
NPHS1 gene, and the mutations within this gene causing congenital nephrotic syndrome of
the Finnish type (CNF), the study of the molecular mechanisms of proteinuria has reached a
new impetus.
Puromycin aminonucleoside (PA) nephrosis of the rat mimics human minimal change
nephropathy (MCN) and is widely used as an animal model of proteinuria. The effacement of
podocyte foot processes is characteristic of these two conditions. Recent studies have
suggested that the slit diaphragm, spanning between the epithelial cell foot processes, is an
essential constituent of the permeability barrier. In this thesis the rat homologue of the human
nephrin complementary DNA (cDNA) was cloned to obtain tools for the molecular analysis
of the experimental diseases. Additionally, the correlation between nephrin messenger RNA
(mRNA) and protein as well as the regulation of an alternatively spliced nephrin mRNA
variant in the experimental models were studied. Finally, the distinct alterations of other
podocyte-associated molecules in the PA nephrosis model were determined.
Cloning of the cDNA for the nephrin rat homologue revealed, in addition to the full-length
nephrin cDNA, the spliced forms, termed α and β. Full-length nephrin and its α splicing
variant mRNAs were shown to be down-regulated in PA nephrosis. The study of the rat
nephrin protein also revealed reduction after puromycin treatment. Nephrin appeared in the
urine 6 and 9 days after induction of PA nephrosis. Study of other podocyte-associated
molecules revealed a set of distinctly regulated molecules. Expression of podocin and CD2-
associated protein (CD2AP) closely resembled to that of nephrin, whereas β1 integrin was up-
10
regulated after administration of PA. In the chronic Heymann nephritis model the expression
levels of the studied molecules, nephrin and CD2AP, were not significantly altered during the
course of the disease.
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INTRODUCTION
Proteinuria is a central clinical feature of renal diseases. In most cases the cause of proteinuria
is a defect in glomerular permeability. The pathogenesis of proteinuria has been studied
intensively for more than a hundred years; however, it still remains unknown. In the late
1950s and the beginning of the 1960s, experimental animal models of glomerular damage
were introduced and became part of routine research. Ever since they have been used to
explore the mechanisms of kidney damage. The PA model of the rat is a well-defined and
extensively studied model of acute proteinuric disease (1) and it also mimics human minimal
change nephropathy (MCN). Another valuable kidney disease model is Heymann nephritis
(HN), a model of human membranous nephropathy (MN) (2). In this immunocomplex
glomerular disease, antibodies against podocyte antigens result in a gradually progressing
disease. In 1998 a protein molecule called nephrin was identified. In a genetic disease,
congenital nephrotic syndrome of the Finnish type (CNF, NPHS1), the gene coding for
nephrin is mutated (3). Mutation in NPHS1 leads either to the lack of the whole protein
product or the expression of truncated forms impairing the specific structure of the foot
processes of glomerular podocytes, and results in proteinuria. In addition to nephrin, other
important podocyte-associated molecules, including CD2-associated protein (CD2AP) (4) and
podocin (5), have since been identified. These discoveries have allowed a new approach to
investigate molecules involved in the pathogenesis of proteinuria. In this study two
experimental models of proteinuria, PA nephrosis and HN, were employed to study the
functional genetics of nephrin and other podocyte-associated molecules.
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REVIEW OF THE LITERATURE
1. Glomerulus as a unique structure for filtration of blood
The functional unit of the kidney is a nephron, of which there are approximately one million
in a human kidney. The main domains of the nephron are the glomerulus, the proximal
tubulus, the loop of Henle, the distal tubulus and the collecting duct. All these segments can
further be subdivided into smaller functional units by morphology. The glomerulus, also
termed the renal corpuscule, is responsible for ultrafiltration of blood. Glomerulus consists of
a branching capillary tuft that is surrounded by a parietal epithelium known as Bowmann´s
capsule. The filtration barrier of glomerulus, through which the ultrafiltration of blood takes
place, is composed of three components: the endothelium, the basement membrane, and the
epithelium (6).
1.1 Development of the glomerular structures
To understand the normal and diseased function of the glomerulus, I next briefly introduce the
development of the kidney. The morphogenesis of the permanent mammalian kidney, the
metanephros, is a reciprocal spatial and temporal phenomenon with several interactions
between epithelial and mesenchymal cells (7, 8). A variety of regulatory factors participate in
the development of the permanent kidney (9). Metanephros developes from two tissue
components: the mesenchymal nephric cord (blastema) and the epithelial, originally
mesoderm-derived, Wolffian duct. First, metanephrogenic mesenchyme induces the
branching of nephric ducts that form the epithelial tubes called ureteric buds. These buds
invade into metanephrogenic mesenchyme and in turn induce mesenchyme to differentiate
into individual nephrons. Developing mesenchyme further induces ureteric bud to elongate
and branch, and it eventually develops into collectiong ducts and the ureter (7, 10).
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Nephrogenesis consists of six distinct stages. The first two stages include the first induction
and condensation, during which mesenchyme cells adhere and condense around the tip of the
ureteric bud. At the third and the fourth stage the condensate mesenchyme gives rise to renal
vesicles, which further develop into the comma-shape body. In the fifth and sixth stages the
structure known as a S-shaped body forms and the tubular part elongates. The farthest cells
from the collecting duct, the future glomerulus, polarize and form lower glomerular cleft from
which the visceral epithelial cells (podocytes) originate. Capillaries diffuse this cleft and the
opposite end of the tubule elongates to form the proximal and distal tubules and the structures
of the loop of Henle (Figure 1) (7).
Differentiation of the metanephros is tightly regulated by a variety of transcription factors,
growth factors and extracellular matrix components (11). Examples of major transcription
factors involved include the paired box gene 2 (PAX2) (12), homeobox genes (HOX), Wilms´
tumor gene (WT-1) (13), and proto-oncogenes N-myc and c-myc (9). Additionally, the
growth factors involved in the regulation of nephron development include e.g. the insulin-like
growth factor (IGF) 1 and 2 (14), vascular endothelial growth factor (VEGF) and
transforming growth factor-β (TGF-β ) (15). Other molecules, such as the homologue of
Drosophila wingless gene 4 (Wnt4), glial cell line-derived neurotrophic factor (GDNF) and its
receptor cRET, as well as some extracellular matrix components have a distinct role in the
development of the metanephros (15).
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Figure 1. Different stages in nephrogenesis. Mesenchyme is aggregated around the tip of
the ureteric bud (A) and further condensates forming a vesicle (B). This vesicle then develops
into comma- (C) and S-shaped bodies with upper and lower cleft (D). Capillaries invaginate
into the lower cleft and start to form a capillary tuft (E) and further develop into glomerulus
(F). (After Saxen, 1987)
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1.2 Endothelial cell layer
The blood is brought to the glomerulus through the afferent arteriole that is eventually split up
into smaller capillaries. The thin endothelial cell layer lines the inside of the capillary wall
and is openly fenestrated (Figure 2). Endothelial cells together with epithelial cells contribute
to the formation of the glomerular basement membrane (GBM) (16). In the rat, the fenestrae
constitute approximately 54% of the total endothelial surface area (17). This endothelium
does not serve as an appreciable barrier to macromolecules; however, it prevents blood cells
from escaping the circulation. Endothelial cells are negatively charged due to the abundancy
of sialic acid (SA)-rich glycoproteins and -lipids. A glycoproteins termed podocalyxin is one
of the known components comprising the polyanionic surface (18).
1.3 Glomerular basement membrane (GBM)
The GBM, the meshwork of extracellular matrix derived from both endothelium and
epithelium, has three layers: lamina rara interna, lamina densa and lamina rara externa
(Figure 2). The thick lamina densa prevents particles equal to the size of albumin or larger
from entering the primary urine, while the lamina rara interna and externa, which contain
anionic sites, prevent charged particles from going through the barrier (19). In addition to its
main components type IV collagen and laminin, the GBM contains nidogen/entactin,
fibronectin, and heparan sulphate (20, 21).
1.4 Epithelial cell layer and slit diaphragm (SD)
The glomerular basement membrane is lined from the urinary space aspect by visceral
epithelial cells that are called podocytes (6). The unique structure of podocytes is divided into
three parts: nucleus-containing cell body, major (primary) processes and foot (secondary)
processes. The latter processes are embracing the capillary loop. The extremely negatively
charged cell membrane of the foot processes is polarized and contains two membrane
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domains, the basal and apical membrane. Between these two domains locates the slit
diaphragm (SD) that connects two foot processes together. The soles of the foot processes are
the only part of podocytes that are in direct contact with the GBM (Figure 2). This basal
membrane part of podocytes has been shown to have intense endocytotic activity (22). The
apical membrane of foot process is covered by glycoproteins and glycolipids that maintain the
separation between foot processes and podocytes to parietal epithelial cells. Between these
interdigitating foot processes locate the slit diaphragm (SD) that are 25- 40 nm wide and 6 nm
thick. SD functions as the final selective apparatus in the filtration mechanism (Figure 2).
Rodewald and Karnowsky have suggested, by analysing EM micrographs, that SD is a zipper-
like construction (23). The exact molecular composition of slit diaphragm was shrouded in
mystery almost twenty years but recently, several studies have revealed new details on
structure and function of SD (See 4. Molecular composition of podocytes).
1.5 Mesangial cells
In addition to endothelial cells and epithelial podocytes the glomerulus contains mesangial
cells that are situated between capillaries and provide support to the glomerulus. Mesangial
cells have also many important functional properties (24) and resemble smooth muscle cells
in many aspects (25). They synthesize matrix components, have phagocytic activity and
participate in the modulation of glomerular filtration. They respond and synthesize vasoactive
peptides, growth hormones, cytokines, bioactive lipids and enzymes (26, 27).
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Figure 2. Schematic presentation of the filtration barrier in the glomerulus. FP; foot
processes, SD; slit diaphragm, LRI; lamina rara interna, LRE; lamina rara externa, LD;
lamina densa; GBM; glomerular basement membrane. The arrow represents the direction of
the ultrafiltration of blood.
2. Proteinuria
The glomerular ultrafiltration of blood, allowing plasma solutes and water to enter the urinary
space but keeping still cells and proteins in circulation, is the first and most important stage in
formation of urine. In human, approximately 150 liters of primary urine is formed daily from
plasma through the glomerular filtration barrier. Some proteins (80 mg/24h) of small
molecular weight always enter the primary urine according to their size and charge. Studies
performed with dextrans and other tracer molecules have shown that small (radius under 20
Å) and neutral molecules, such as inulin, enter freely the urinary space. The glomerular
filtration barrier is less permeable to uncharged molecules ranging between radii 20-50 Å (28,
urinary space
F SD
LRI
LRE
LD
capillary vessel
GBM
FP
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29). Albumin, with its heavy negative charge and a radius of 36 Å, is predominantly retained
in circulation but often appears in urine in various disease states (28-31). Proteinuria is
defined as a leakage of proteins into the urine. It is measured by the amount and/or content of
proteins in urine, and is of either glomerular or tubular origin, glomerular injury being a
primary reason for proteinuria. In glomerular injury, the permselectivity of a glomerulus is
altered, and the plasma proteins leak to primary urine (32, 33). Alterations in any structural or
functional component of the glomerular filtration barrier can lead to proteinuria (31, 34).
Normally small amounts of proteins leak into the urinary space, but these proteins are
reabsorbed by proximal tubular cells. The reabsortion can fail, for example, due to metallic
ions and cause tubular proteinuria (35).
2.1 Causes of proteinuria
Proteinuria, being the one of the hallmarks of nephrotic syndrome, may be caused by various
mechanisms including immunological, toxic, metabolic or hereditary (36). In immunological
mechanisms, inflammatory tissue damage is mediated e.g. by circulating and infiltrating
macrophages, lymphocytes and platelets (34, 37). These circulating cells can also cause the
glomerular injury via reactive oxygen species (ROS) and cause glomerular hypercellularity.
Non-inflammatory immune damage includes antibodies against GBM and glomerular cell
membranes with or without the involvement of the components of complement (34, 37).
Immune injury starts with the formation of immune deposits and can lead to the activation of
complement that finally end up in the assembly of the membrane attack complex (MAC, C5b-
9). MAC promotes the epithelial cell and GBM damage as seen in membranous nephropathy
(MN), the human autoimmune disease, and minimal change nephropathy (MCN), common
childhood proteinuric disease (34, 37, 38).
Transient or haemodynamic proteinuria can be observed after heavy exercise, in patients with
heart failure and with fever condition (35). Massive and persistent proteinuria, the excretion
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rate of which exceeds over 3.5 g/24 hours protein in urine, lowers the concentration of plasma
proteins, including albumin, which is one of the most important components maintaining the
osmotic balance. The results are hypoalbuminemia and reduction of oncotic pressure of
plasma, which in turn, leads to edema. Activation of the rennin-angiotensin system, increased
aldosterone secretion and cholesterol synthesis, i.e. hyperlipidemia, are consequences. All
these together give rise to the nephrotic syndrome (35).
2.2 Congenital nephrotic syndromes
Congenital or infantile nephrotic syndromes are rare renal diseases already manifested during
the first years of life.  Symptoms, including proteinuria, hypoproteinemia and edema, are
signs of congenital nephrotic syndrome (CNS), and become manifest soon after birth and
before the age of three months. CNS, a heterogeneous group with a variety of kidney
disorders, is classified as primary or secondary, e.g. acquired, inherited, or sporadic, diseases.
One example of primary nephrotic syndrome occurring within first 3 months of life is the
congenital nephrotic syndrome of the Finnish type (CNF). When compared with other
nephrotic syndromes that occur in the later ages, the prognosis of CNS is poor with a need of
nephrectomy and renal transplantation (39, 40).
Secondary nephrotic syndrome can be caused by systemic diseases, such as diabetes mellitus
and amyloidosis, microbial infections or toxins (36, 41).
2.3 Congenital Nephrotic Syndrome of the Finnish type
In 1956 Hallman et al. described for the first time the congenital nephrotic syndrome of the
Finnish type (CNF, NPHS1) that belongs to the Finnish disease heritage (42). Compared with
other congenital nephrotic syndromes CNF has not only the common symptoms but also has
distinctive features and pathological findings. It is an autosomal recessive disease with an
20
incidence of 12 per 10000 births in Finland (43). Few sporadic cases have been reported
randomly in the world, especially in the United States (44-46).
2.3.1 Clinical aspects
The most important clinical hallmark of CNF patients is massive proteinuria, starting already
in utero. The affected infants are born prematurely by the 36th gestational week and the
placenta is typically enlarged (47). These newborn patients present edema, hypoalbunemia,
and hyperlipidemia (43). Additional symptoms include abdominal distension, ascites,
umbilical hernias and developmental retardation. The loss of immunoglobulins predisposes to
frequent infections (44) and before 1980s the outcome of CNF was invariably fatal. Later,
substitute treatment with proteins and nutrients, followed by bilateral nephrectomy and
ultimately renal transplantation has prolonged the life expectancy of CNF patients and
dramatically changed the disease outcome: the patients do not appear to develop additional
symptoms in other organ systems (48).
2.3.2 Pathology of CNF
The pathology of CNF has been under intensive research for decades but the molecular
mechanism of the disease has remained unknown until recently (see Genetics of CNF). In
foetal CNF kidneys the organogenesis and nephrogenesis do not seem to differ from normal
kidneys (49). However, the representative morphological changes are that CNF neonates have
2-3 -fold larger kidneys than normal, with increased number and relative volume of glomeruli
(49).
In several light microscopy studies the apparent morphological changes in CNF are mesangial
cell hyperplasia, including accumulation of mesangial matrix, dilatation of proximal tubules
and tubular atrophy (40, 49, 50). Out of these, particularly, dilated proximal tubuli are the
consequence of protein leakage into urine (42). In electron microscopy studies, flattening of
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podocyte foot processes has been constantly observed (51, 52). In additon, an increased
number of endocytotic droplets  has been observed in endothelial cells and electron lucent
vacuoles in mesangial cells (52). Reports on the thickness of GBM in CNF patients are
contradictory. While Autio-Harmainen and Rapola reported thinning of GBM (53), Ljungberg
et al. could observe light thickening of GBM (54). The constant proteinuria eventually leads
to the fibrotic kidneys in the course of nephrosis (55).
2.3.3 Diagnosis and treatment
The prenatal diagnosis was developed to measure the high concentrations of α-fetoprotein in
maternal serum or amniotic fluid (56, 57). However, raised α-fetoprotein levels imply not
only CNF but also other foetal disorders such as defects in neural tube or abdominal wall.
Poor screening methods have given false positives and led to abortions of healthy foetuses.
The identification of the NPHS1 gene and its localization to chromosome 19 has allowed a
more accurate diagnosis of the disease that can be performed on the 12th or 13th gestational
week by PCR-restriction fragment length polymorphism (PCR-RFLP) and a dual colour
oligonucleotide ligation assay (OLA) (58, 59).
The diagnosis of CNF can be set postnatally by large placenta, occurrence of proteinuria,
exclusion of other types of CNS, positive family history and normal glomerular filtration rate
during the first six months of life (48).
The only life-saving treatment for the CNF patients is early bilateral nephrectomy and
subsequent renal transplantation (44, 48). Following nephrectomy the patients must remain on
continuous cyclic peritoneal dialysis and nutritional correction until their body weight reaches
7 kg, after which they are suitable for transplantation. The regular transplantation treatment
for CNF began in 1985 in Finland (44, 48).
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2.3.4 Genetics of CNF
Several basement membrane components (54, 60) as well as embryonic developmental and
differentiation factors (61) have been studied as potential gene defects causing CNF. Heparan
sulphate proteoglycans (HSPG) partly produce anionic charge of GBM, but a defect in HSPG
has been excluded as a potential cause of CNF (54) as well as PAX2 that is coding for a
paired-box transcription factor expressed during the development of the kidney (61-63).
 The gene defect of CNF was localized to the long arm of chromosome 19, location at
19q13.1, with disequilibrium analysis (64, 65). In 1998, a 26-kb sequence encoding nephrin
(NHPS1) was identified by Kestilä et al. (3). 94% of CNF cases in Finland are caused by two
nephrin mutations: FIN
major (nt121delCT) results in an early stop codon at exon 2 causing a
frameshift and a failure to express the full-length molecule. FIN
minor (R1109X) causes a
nonsense mutation in exon 26 encoding the intracellular part of nephrin in residue 1109 (66,
67). In addition to these, roughly 50 different point mutations in the coding region of NPHS1
have been reported (68, 69).
2.4 Minimal change nephropathy
Minimal change nephrotic syndrome (MCN), previously also called lipoid nephrosis (70), is
the most common primary nephrotic syndrome of childhood worldwide. The disease
manifests usually in early childhood, from 2 to 6 years of age with a incidence of 1.8-5
cases/1000000/year. For unknown reasons, MCN is more common in Asian and Arab
populations (36).
The main clinical finding of MCN is significant proteinuria that exceeds 40 mg/hr/m2.
Microscopic hematuria is found in 1:5 of cases. Raised serun lipid concentrations including
cholesterol, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and
triglycerides, are usually observed (36). When studied by light microscopy the overall
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morphological changes appear negligible. In EM studies a profound change is the effacement
of podocytes while GBM is mostly unaltered. Lipid droplets are found in proximal tubules.
The risk to develop MCN is higher if the child is atopic and has HLA B12 antigen. Systemic
diseases, e.g., syphilis, HIV and solid tumours are known to cause minimal change lesions
(36).
Little is known about the pathogenesis of MCN. It is assumed that autoimmune mechanisms
cause this kidney disease, since also abnormal function of T-lymphocytes can be the cause of
the symptoms (71). In most cases the MCN responds to corticosteroids and therefore minimal
change patients are mainly treated with corticosteroids. Sometimes alkylating cytotoxic drugs
are required (72).
3. Experimental models of proteinuria
Cell culture approaches have given a great amount of useful information about the function
and structure of the kidney but they do not provide information on the complex physiological
interactions in vivo. Over time, the cultured renal cells lose their cell-specific markers and
morphology. Glomerular podocytes are particularly difficult to culture. In addition, the lack of
fresh human kidney material, obtained from biopsies or autopsies, has forced researchers to
look for other ways of studying kidney diseases. More than forty years ago a number of
animal models of human renal diseases was taken into routine use. The reproducibility has
made experimental models indispensable in renal disease research. The PA-induced model of
acute nephrosis, and brush border (BB) antigen-induced HN, a chronic model of nephritis, are
the most used and well-defined.
3.1 Puromycin aminonucleoside nephrosis
In 1959 Vernier et al. reported on changes in kidney glomeruli in the aminonucleoside
nephrosis of the rat (73). This classical PA nephrosis model of the rat mimics human MCN by
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its histology and ultrastructure. PA nephrosis can be induced with either a single or repeated
PA injections that result in bulky proteinuria in rats starting around day 3-4 post-injection;
proteinuria peaks around day 10 and resolves by day 28 (74). In addition to proteinuria in PA
nephrosis, morphological alterations in podocytes are detected in glomeruli by
histochemistry, immunohistochemistry and immunoelectron microscopy.
3.1.1 Morphological changes in PAN
In general the dilatation of the proximal, distal and collecting tubules and, furthermore,
thickening of the GBM are detected under light microscopy studies. In a more detailed study,
the effect of PA on epithelial visceral cells is drastic, including reduction in the number of
foot processes resulting from fusion or retraction of the processes (73, 74). In addition to this
early change, SDs are altered, dislocated or lost. At the same time, the appearance of
occluding-type junctions is evident. The remaining SDs are located above these junctions
(75). Later, during the course of the disease, formation of vacuoles due to increased
endocytotic and lysosomic activity is seen. Further on, the number of phagosomes is
increased and the epithelium is detached from GBM (75). The growing cytoplasmic balloon-
like vacuoles finally rupture allowing GBM a direct contact with the urinary space (76). The
difference in the course of PA nephrosis between continuous daily administrations and a
single intravenous injections of the drug is seen in the early and late changes of morphology.
3.1.2 Pathogenesis and molecular changes in PAN
The target of puromycin aminonucleoside in the kidney is podocyte-specific. Although
several studies have been performed concerning the molecular pathogenesis, the exact
molecular mechanism through which PA influences the podocytes is still unknown.
The role of reactive oxygen species (ROS) and lipid peroxidation mediating the glomerular
injury in PA nephrosis has been under extensive study. In vitro analysis shows generation of
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O2-, H2O2 and OH- in glomerular epithelial cell culture and rat kidney slices (77, 78). The
involvement of the xanthine pathway as a mediator of PA nephrosis has been debated (79).
Fawcett et al. and Pedraza-Chaverri and colleagues showed a connection between lipid
peroxidation and proteinuria in PAN (80, 81) and it was shown that antioxidants, for example
probucol, were shown to significantly reduce renal injury and proteinuria (79, 82-84)
In the course of PAN, rats show overall molecular changes in glomerular podocytes. Earlier
studies have concentrated mainly on changes of the molecular architecture in GBM that
consists mainly of HSPG. In 1986, Mahan et al. showed reduction in anionic charge sites of
HSPG in PAN treated rats (85). In addition, a significant 75% reduction of SA on plasma
membrane was detected after induction of PA nephrosis (86). Whiteside et al. reported
contradictory data of the molecular changes and reduced HSPG or SA content in PA
nephrosis (87). They concluded that epithelial detachment led to the development of
proteinuria, not the changes in GBM.
The crucial role of SD in ultrafiltration of blood shifted the focus onto SD molecules in the
pathogenesis of PA nephrosis. Zonula occludens-1 (ZO-1), a protein of tight junctions,  has
been intensively studied (88-91). After PAN induction, ZO-1 appears to dislocate from SDs
and has been found in de novo-formed occluding junction below SD (89, 92). An integral
membrane glycoprotein maintaining the unique structure of podocytes, podoplanin, is
downregulated in PAN (93). Takeda et al. reported that disconnection of a highly
glycosylated CD34-related transmembrane protein, podocalyxin, from the actin cytoskeleton
due to the loss of its negative charge led to the changes in foot processes (94)
3.2 Mercuric chloride (HgCl2) induction
Mercuric chloride (HgCl2) is classified as a nephrotoxin  and proximal tubular cell damage is
a major outcome after administration of HgCl2  (17, 95, 96). HgCl2 toxicity involves
influences on sulphydryl groups, phospholipid membranes and lysosomes (97-99). In chronic
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exposure, HgCl2 is accumulated intracellularly in lysosomes of the kidney (97). In most cases
HgCl2 injury causes the depletion of glutathione that protects from oxidative renal damage
(100, 101). Additionally, Nath et al. observed increased hydrogen peroxidase production
(101, 102) that further leads to the progression of renal injury. Mercuric chloride affects the
function of mitochondria in the kidney and in T-lymphocytes (101). The dosage of 5 mg/kg of
HgCl2 given to animals subcutaneously suppresses the rate of adenoside 5´-triphosphate
(ATP) synthesis (95). HgCl2 can also cause membranous nephropathy and anti-glomerular
immune deposits (103). In T-lymphocytes, it induces apoptosis via mitochondrial malfunction
(104).
3.3 Heymann nephritis
The authentic Heymann nephritis (HN) is an experimental renal disease in rats mimicking
common MN in adults (2). Similarly to the human disease HN is classified as an autoimmune
disease with production of subepithelial immune deposits. The formation of immune deposits
on the podocyte cell surface can be considered a failure of endocytotic pathway (105).
Activation of C5b-9/MAC occurs during the progress of the HN causing proteinuria (22, 105,
106). HN can be induced in two ways: passively and actively. In the active HN, rats are
injected with a crude extract of proximal tubular BB antigen, Fx1A, whereas in the passive
form of HN rats are injected with anti-Fx1A antibodies.
The antigen gp330, also called megalin, has been shown to be essential for the induction of
HN (107). The 515 kDa protein gp330/megalin is located in invaginations of microvilli of the
brush border of the convoluted proximal tubule. It forms antigen-antibody deposits at the
clathrin-coated pits in GBM. The glycoprotein gp 330/megalin is related to the low-density
lipoprotein receptors and links with a 44-kDa receptor-associated protein, RAP (22, 107)
Antibodies directed against lipid antigens that associate with immune deposit-forming
gp30/megalin immune complexes activate complement C5b-9. MAC presumably causes
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4.1 Nephrin
Nephrin is a transmembrane protein encoded by NPHS1, and with 1241 amino acids, whereby
the calculated molecular size of nephrin is 132.5 kDa in human. After post-translational
modifications, such as glycosylation, the size of nephrin increases to about 185 kDa when
detected by Western blotting. Nephrin belongs to the immunoglobulin-like superfamily of
proteins and has typically eight extracellular immunoglobulin-like modules, a fibronectin type
III motif, a transmembrane part, and an intracellular domain with tyrosine phosporylation
sites (3). Nephrin is primarily located at SD (109-111). It is suggested that nephrin
participates in cell-cell or cell-matrix adhesions. One hypothesis is that nephrin acts as a
major functional component of the glomerular filtration barrier in SD. Further, it is proposed
that nephrin binds to another nephrin of the opposite site podocyte, forming a ladder-like
structure (111). Mutation in NPHS1 leads to incomplete development of the kidney, lacking
SDs (112). Simons et al. reported nephrin phosphorylation to be associated with lipid rafts,
compartment of cell membranes enriched with glycoshingolipids, cholesterol, and signalling
molecules (113). Additional proposed function for nephrin is involvement in cell signalling
with podocin (114). In addition to the kidney, nephrin protein expression is found in human
pancreas, newborn mouse cerebellum, and mouse testis (115-117).
4.2 CD2AP
CD2-associated protein (CD2AP) is an 80kDa soluble adapter protein expressed in a great
variety of tissues (118, 119). CD2AP contains three SH-domains at the amino terminus that
are needed in protein-protein interactions. This suggests a possible regulatory or signalling
function for CD2AP. In the adult kidney it is located mainly in glomeruli and is also found in
the proximal and distal tubuli, as well as the collecting duct (119). Acting as a link between
adhesion proteins of the immunoglobulin superfamily and the cytoskeleton, CD2AP has
numerous binding partners. It has been reported to be coexpressed with nephrin (120, 121)
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and to bind actin (Lehtonen et al. in press). For the normal kidney organogenesis CD2AP has
been shown to be crucial, especially in developing podocytes (120). It interacts with
polycystin-2 gene and can be associated with type 2 polycystic kidney disease (119). CD2AP
knockout mice develop nephrotic syndrome with proteinuria at the age of two weeks and they
die at the age of six to seven weeks. Morphological changes in CD2AP knockout mice
include fusion of the foot processes, mesangial deposits and proliferation similar to CNF (4).
4.3 Podocin
The NPHS2 gene, which has been mapped to the long arm of chromosome 1, encodes a
42–kDa integral membrane protein called podocin (122). When mutated, it is responsible for
an autosomal recessive steroid resistant nephrotic syndrome (5). Podocin belongs to the
stomatin protein family, the members of which form homo-oligomers, and is solely expressed
in developing and mature podocytes. A predicted structure of podocin is a hairpin-like
molecule with a cytosolic N- and C-terminus. It functions as a link between the cytoskeleton
and SD. Podocin has been suggested to interact with other proteins, e.g. α-actinin and nephrin
(114, 123-125). It has been shown that podocin enhances the signalling events by nephrin
(114). Recently it was reported that podocin is clusterred in lipid rafts in SD (125).
4.4 Alpha-actinin-4
Four isoforms of α−actinin-4 have been identified (126). These actin-associated proteins
crosslink actin filaments into bundles. The gene, ACTN4, encodes a cytoplasmic protein, α−
actinin-4  (126) Honda et al. found that α− actinin-4 was more concentrated in filopodia of
the cell (126). This non-muscle isoform of actinin is essential for cell motility and cancer
invasion. Furthermore, it plays a role in endocytosis (126, 128). In the glomerulus, α-actinin-
4 indirectly anchors actin filaments of podocytes to GBM (129, 130). In in vitro analysis, a
mutant α-actinin-4 adheres more intensively to filamentous actin than the wild type α-actinin-
4 (127). Mutation in ATCN4 gene produces renal defect known as familial focal segmental
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glomerulosclerosis (127). α-actinin-4 has several interaction partners, including zyxin (131)
and a cerebral transmembrane protein densin (132).
4.5 Integrins
The family of cell surface proteins called integrins is wide and versatile. These molecules
share a common function of attaching cells to the extracellular matrix. Integrins form
heterodimers consisting of two subunits, α and β  (133, 134). There are several α and β
subunits identified. The heterodimers cannot form in a random manner: certain α  subunits
require certain β subunits. Integrins are expressed in various tissues and have a variety of
ligands (133, 134). In podocytes, especially α3β1 integrin is found at the soles of the
processes. It attaches the cytoskeleton to GBM by binding laminin–1, collagen types I and IV,
fibronectin or entactin/nidogen (135). The cytoplasmic site of β1 integrin has a binding site
for a α− actinin-4 forming a link between actin cytoskeleton and integrins (129). Mice
deficient (knockout) for α3 subunit fail to develop functionally or morphologically normal
foot processes (136, 137).
4.6 Dystroglycans
Dystroglycans (DG) were first characterized in skeletal muscle cells associated with the
dystrophin complex (138). DG function as a crucial link between the actin cytoskeleton and
extracellular matrix (139). After post-translational modifications DG is cleaved into two
forms: a peripheral membrane form α  and a transmembrane form β. DG have various
binding partners in the extracellular matrix, for example laminin-2,4 and agrin (140). They are
involved in arenavirus infections by binding viruses directly, and are needed for entry of
Mycobacterium leprae into Schwann cells (141). In non-muscular cells DG supports the
assembly of the extracellular matrix, i.e. basal lamina, where they bind laminin-1, perlecan
and agrin (140). DG are highly expressed in soles of the foot processes of glomerular
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podocytes. DG knockout mice fail to develop Reichert´s membrane, extra-embryonic
basement membrane, during early embryogenesis, and they die at embryonic day 6.5 (142).
Due to this, chimaeric mice deficient for DG were constructed and they developed muscular
dystrophy (143).
Table 1. The list of molecules linked to podocyte foot prosesses
molecule location type function
NHERV-2 apical membrane domain IC link between podocalyxin and actin
Ezrin apical membrane domain IC link between podocalyxin and actin
Glepp-1 apical membrane domain TM membrane phosphatase
Catenins apical membrane domain IC associations with P-cadherin
P-cadherin slit diaphragm domain TM component of slit diaphragm
FAT slit diaphragm domain TM component of slit diaphragm
Neph-1 slit diaphragm domain TM component of slit diaphragm
Nephrin slit diaphragm domain TM component of slit diaphragm
CD2AP slit diaphragm domain IC association with nephrin
Podocin slit diaphragm domain IM association with nephrin
ZO-1 slit diaphragm domain TM component of slit diaphragm
Dystroglycan basal membrane domain TM receptor for extracellular matrix
α3β1 integrin basal membrane domain TM receptor for extracellular matrix
Vinculin basal membrane domain IC link between cytoskeleton and integrin
Paxillin basal membrane domain IC link between cytoskeleton and integrin
Talin basal membrane domain IC link between cytoskeleton and integrin
gp330/megalin basal membrane/ GBM TM endocytic receptor for lipoprotein
MAGI-1 basal membrane domain IC association with megalin
Utrophin basal membrane domain IC link between DG and actin
Sarcoglycans basal membrane domain TM link between DG and integrins
Podoplanin cell membrane IM not known
α-Actinin-4 actin associated IC cross-link actin filaments
Cortactin actin associated IC association with Arp2/3
Arp2/3 actin associated IC nucleate new branch of filament
Synaptopodin actin associated IC association with actin microfilaments
IC intracellular protein; TM transmembrane protein; IM integral membrane protein
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5. RNA processing
Multicellular organisms contain the same genome in every cell and need a special machinery
to express a subset of genes in a cell type-specific and developmental stage-specific manner
(144-146). mRNA delivers a message from the nucleus to the cytosol to be translated into
proteins. Mature mRNA is not an exact copy of a specific gene, but has undergone a series of
structural and chemical modifications, which are termed RNA processing (145). This
processing takes place during transcription or afterwards as post-transcriptional modification.
Some of the processing mechanisms, such as capping and polyadenylation, are examples of
end modifications, whereas splicing is an example of internal modification (Figure 4.) (146).
Multiple proteins, such as the spliceosome and polyadenylation enzymes, take part in the
processing (144, 145).
Figure 4. RNA processing. Step 1. The exact copy of genomic DNA is transcripted into
precursor mRNA and ended by any of the termination sites. Immediately after transcription
7–methylguanosine (CAP) is added to 5´-end. Step 2. The excess of 3´end termination sites is
removed and polyadelynate-tail (polyA-tail) is added to 3´end. Step 3. Introns are removed
i.e. RNA is spliced.
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5.1 Origin and processing of RNA splicing
Prokaryotic cells have a continuous genome, whereas in eukaryotic life forms the coding
regions of the genes, exons, are usually intercepted by non-coding regions, called introns
(144). During transcription, both exons and introns are copied into pre-mRNA. To remove
introns, pre-mRNA is specifically spliced. There are four classes of introns classified
according to the mechanisms of their splicing: self-splicing introns I-III and nuclear pre-
mRNA introns (144). Self-splicing is autocatalytic and is usually found in mitochondrial and
ribosomal RNA molecules (144) (146).
The splicing of nuclear pre-mRNA is a complex event catalysed by spliceosomes (147, 148).
The spliceosomes contain five small nuclear ribonucleoproteins (snRNPs) and a great number
of small nuclear RNA (snRNA) molecules. In addition to these proteins splicing needs an
association with non-snRNP splicing factors, such as serine/arginine-rich (SR) proteins and
the U2 auxiliary factor (U2AF) (147, 148).
The splicing sites are conserved sequences at the 5´-end and 3´-end (usually GU and AG,
respectively) of the introns (144, 146). In the middle of an introns is a so-called branch point
sequence (BPS) that is also needed in splicing. The splicing starts with 2´-hydroxyl group of
adenylate residue at the branch point sequence attacking the phosphodiester bond linking the
upstream exon (5´end) to the intron. A 2´, 5´-phosphodiester bond is formed between this
adenylate residue and the 5´-end guanydylate, the donor site of the introns, and this
intermediate structure formed is called lariat. Then the 3´-hydroxyl group attacks the
phosphodiester bond between an intron and the downstream exon (3´end), so that upstream
exon and downstrean exon are joined together. This releases the introns, which is
subsequently degraded (Figure 5.) (144, 146).
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Figure 5. Splicing reaction. Step1. Attack of the 2-hydroxyl group of branch point
adenylate. Step 2. Lariat formation through the transesterification reaction. Step 3.
Ligation of exons and release of lariat. See details in text under the origin and
processing of RNA.
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5.2 Alternative splicing
In 1978 Gilbert et al. discovered that several mRNAs encoding multiple proteins with
differing functions can be produced by combining exons differentially from a single gene
(149). This significant gene function-modifying mechanism, still poorly known, is termed
alternative RNA splicing. Alternative splicing plays a significant role in cell type-specific
gene expression patterns, apoptosis, as well as in development and several other physiological
conditions (150). Alternative RNA splicing has been found in viruses, invertebrates and
vertebrates. Alternative splicing substantially increases genetic complexity, especially in
higher eukaryotes (150). It has been studied mainly in the nervous and immunologic systems,
where a vast diversity of proteins, particularly in the case of cell surface receptors, can be
achieved. The human genome project has reduced the estimation of gene number down to
30000 (151). Recent studies have estimated that 42-57% of human genes are alternatively
spliced (152). The diversity of protein isoforms cannot be explained solely by the expression
of different members of multigene families. This emphasizes the significance of alternative
splicing, in addition to RNA editing and post-transcriptional modification, as a producer of
greater number of protein isoforms.
Alternative splicing is defined as a choice of splice sites (Figure 6). Splicing patterns can
occur in several ways, e.g., the use alternative 5´splice sites, alternative 3´splice sites, optional
exons, mutually exclusive exons and retained introns. The exclusion of 5´-exon(s) by
alternative promoter usage switches sex in Drosophila (153). The exclusion of 3´-exon by
alternative polyadenylation site usage produces calcitonin or calcitonin-gene-related peptide
in mammalian cells (154). The exon skipping can influence rat brain axon outgrowth during
the development (155). The mutual exon exclusion alters binding specifity of growth factors
in prostate cancer (156). Alternative splicing can also introduce premature stop codons.
Alterations in the splicing pattern can be a response to extra- and intracellular signals. It is
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Figure 6. Alternative splicing. A) Alternative promoter usage changes sex orientation and
behaviour in Drosophila. Upstream 5´initiation codon usage leads to female phenotype
whereas downstream start codon usage leads to male character. B) Alternative
polyadenylation site usage yields either thyroid calcitonin production or neuronal calcitonin-
gene-related peptide production. C) Exon skipping represses neuronal outgrowth in rat
embryonic brains. D) Mutual exclusion of exons changes the affinity of fibroblast growth
factor receptor 2 to keratinocyte growth factor (KGF) or fibroblast growth factor (FGF). E)
Retaining of intron. Female-specific retention of intron switches off the gene termed male-
specific-lethal (msl-2) expression. (Modified from Smith CW and Valcarcel, 2000)
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poorly known at present what the signals regulating splicing alterations or the factors utilized
in alternative splicing are (150).
Below some examples of alternative splicing are described leading to increased protein
diversity in different tissues. In the nervous system alternative splicing leads to differences in
neurotransmission, protein localization, ion channel activation, protein phosphorylation and G
protein coupling (157). Drosophila Dscam, a receptor of the nervous system, is a member of
the immunoglobulin superfamily. Alternative splicing produces multiple isoforms of this
protein and regulates its adhesion to other molecules (158). During the development of
humoral immune system, alternative RNA splicing causes the switch of a membrane-bound
antibody to a secreted form lacking the transmembrane domain.
Alternatively spliced molecules have been identified also in the kidney. The kidney
development in mice shows the proportion-dependent different expression of splicing variants
of Wilms´ tumour gene 1 (WT1). It produces a tumor suppressor zinc finger protein, but it is
also important in embryonic development, and when mutated it leads to formation of
nephroblastomas. The tightly controlled alternative splicing results in insertion or omission of
the three amino acids lysine (K), threonine (T) and serine (S); the two isoforms have distinct
functions (159).
Another example of alternative splicing during kidney development is the differential
expression of RET receptor tyrosine kinase splicing variants (160). RET expression is at its
highest in early gestation and regulates the ureteric branching in morphogenesis of the kidney.
Skipping of exons encoding extracellular area results in a truncated or soluble form of RET,
which can affect ligand binding (160). Soluble RET receptor can also participate in antiviral
protection (161) as certain isoforms can function as type 1 interferon receptors.
Angiotensin II type 1 receptor is expressed in a great variety of tissues, including the kidney.
Angiotensin II participates for instance, in fluid homeostasis, control of aldosterone
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production and renal function. Angiotensin II type 1 receptor mRNA has four alternative
splicing variants. These four variants vary in their exon content. Martin et al. showed that the
expression and the affinity to ligand of the long and short splicing variant differs according to
their location in tissues (162).
The study of the functions of multiple isoforms caused by alternative splicing has extended in
recent years and is continuing. The determination of choice of splice site and the regulatory
factors involved in alternative splicing still remain largely undiscovered.
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AIMS OF THE STUDY
The major hallmark in the impairment of the glomerular filtration barrier is proteinuria. The
molecular mechanisms of proteinuria are still unknown. Discovery of the NPHS1 gene
encoding nephrin that is mutated in CNF, provided a new tool to the research of kidney
diseases. The aims of this study are listed here:
-to characterize the rat nephrin homologue;
-to study the regulation of the rat nephrin mRNA in experimental models of proteinuria of
acute PA nephrosis and chronic HN;
-to study the regulation of alternatively spliced nephrin mRNA in PA nephrosis;
-to analyze the alterations in nephrin protein expression in experimental models;
-to explore the involvement of additional podocyte-associated molecules in PA nephrosis
model;
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MATERIALS AND METHODS
1. Animals
Young male or female rats of the Sprague-Dawley strain, weighing 250-280g, (Department of
Bacteriology and Immunology, University of Helsinki) were used throughout the study. The
rats were housed in controlled temperature and humidity. They were fed with standard rodent
chow and had free access to tap water.
2. Antibodies
The primary monoclonal and polyclonal antibodies are presented in Table 1. The secondary
antibodies are presented in Table 2.
Table 1. Primary antibodies used in the studies
Antibody Antigen Source Dil. Used in
extra-1 (030) nephrin rabbit polyclonal IgG, aa 780-772, 2,4 mg/ml 1:300 III
extra-2 (043) nephrin mouse monoclonal IgG, aa 765-772, 4,6 mg/ml 1:600 IV
PAM243 (intra) nephrin rabbit polyclonal peptide-specific serum, aa 1101-1126 1:50 I, II
extra-2 (7E9) nephrin mouse monoclonal IgM, aa 748-772, 4,6 mg/ml 1:50 V
anti-β1 integrin β1 integrin mouse monoclonal IgG, BD Transduction laboratories 1:2000 IV
anti-β-catenin β-catenin mouse monoclonal IgG, BD Transduction laboratories 1:1500 IV
anti-podocin podocin rabbit polyclonal, Dr.Corinne Antignac 1:2000 IV
anti-α-actinin-4 α-actinin-4 mouse monoclonal IgG Dr. Tesshi Yamada 1:600 IV
anti-α-dystroglycan α−dystrogl. mouse monoclonal IgG, Upstate Biotecnology 1:100 IV
R1774 CD2AP rabbit polyclonal antiserum, aa 6-574 1:400 V
R211 CD2AP rabbit polyclonal antiserum, aa 1-330 1:400 V
anti –CD2AP CD2AP rabbit polyclonal IgG, aa 350-369 1:5 V
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Table 2. Secondary antibodies used in the studies
Antibody (Source) Dil. Used in
Fluoresceinisothiocyanate (FITC)-conjugated affinity purified goat anti-mouse IgG (Dako) 1:50 IV
FITC-conjugated affinity purified swine anti-rabbit IgG (Dako) 1:50 IV
FITC-conjugated affinity purified rat anti-rabbit IgG (Dako) 1:50 II
FITC-conjugated affinity purified rat anti-rabbit IgG (Boehringer-Mannheim) 1:50 I
Horse radish peroxidase (HRP)-conjugated affinity purified swine anti-rabbit IgG (Dako) 1:2000 III, IV
HRP-conjugated affinity purified rabbit anti-mouse IgG (Dako) 1:2000 IV
Rhodamine (TRITC)-conjugated aff. purified goat anti-rabbit IgG (Jackson Immunoresearch) 1:2000 V
3. Primers
The primers were used as presented in Table 3.
Table 3. Sequence-specific oligonucleotide primers used in the studies
Forward primer (For) , Reverse primer (Rev)
cDNA Code Sequence Used in
human nephrin NPHS-2606U5´-CCAACATCGTTTTCACTTGG-3 I
 NPHS-3515L 5´-GGGAAGGCCATATCCTCA´-3´ I
rat nephrin RN-S1 5´-CCACCTCAGCACCTCGAG-3´ I
 RN-AS1 5´-GAGACACGAGCTCGGGACC-3´ I
 RN-S2 5´-TCCAGGTCTCCGTCACTACC-3´ I
 RN-AS2 5´-GGCCATAGGCTCTCTCCACT-3´ I, III
 RN-S3 5´-AGCCTCTTGACCATCGCTAA I, II, III
 RN-AS3 5´-CCCAGTCAGCGTGAAGGTAG-3´ I, II
 RN-S4 5´-CTGCTGCCTGTGCTCTTTGC-3´ I
rat nephrin R-TM-2709U 5´-TAATGTGTCTGCGGCCCAG-3´ III
rat nephrin R-TM-2783L 5´-TTGGTGTGGTCAGAGCCAAG-3´ III
 rat α-nephrin RN-alpha 5´-GTCCTCGCCTTCAGCACCTG III
α-actinin-4 For 5´-TATCACGCGGCGAACCA-3´ IV
 Rev 5´-TCATCCTCCTGGGCCATGT-3´ IV
P–cadherin For 5´-TCCATCATTGTGACAGACCAGAA-3´ IV
 Rev 5´-AGGCATTACTCCCTCCAGA ACA-3´ IV
α-dystroglycan For 5´-GGACGCGAGGTGCCATT-3´ IV
 Rev 5´-CAGGAACCGTGGTACCAGCTT-3´ IV
podocin For 5´-AATTCCTTGTGCAAACCACTATGA-3´ IV
 Rev 5´-CCAAGGCAACCTTTGCATCT-3´ IV
β1-integrin For 5´-CTCTCCAGAAGGGTGGCTTTG-3´ IV
 Rev 5´-TCTCCTGTCCCATTCACTCC-3´ IV
CD2AP-1 For 5'-GAATGGGAGTGAACCTGCTC-3' V
Rev 5'-CAGTTCACCCTTCCACCAGC-3 V
CD2AP-2 For 5'-GAACTTTACACTGACGC-3´ V
Rev 5'-ATGGTTGACTATATTGTGGAGTATGAC-3' V
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4. Methods
4.1 Animal experiments
4.1.1 PAN with modification with HgCl2 and probucol (I-V)
Rats in experiment II (PA+HgCl2+probucol) were given a single intraperitoneal injection of
puromycin (PA 15 mg/100g, Sigma Chemicals, St. Louis, MO, USA) and/or mercuric
chloride (HgCl2 0,5 mg/100g, Sigma Chemicals) with or without prior daily probucol (Sigma
Chemicals) treatment for ten days before PA/HgCl2 injection. Probucol was given in diet (2%
wt/wt) mixed in the pellets and the consumption was recorded daily. The control group
received 0.9% saline i.p. in equal volume at day 0 of puromycin injection. Urine was
collected using metabolic cages at day 0, 3, 6 and 9. From every group three animals were
sacrificed at day 3 and 10 as indicated in Table 1 in study II. Tissue samples for
immunoelectron microscopy were also taken at day 7.
4.1.2 Induction of Heymann nephritis (II, V)
The modification of HN with NO synthase inhibitor (L-NAME) was induced with purified
BB antigen (1 mg) according to the time schedule presented in Table 1 in study II and is
previously described (163). Rats developed Heymann nephritis within 4 weeks.
4.2 Quantitation of urinary albumin (I-V)
To insure that the induction of nephritis was successful, urinary albumin was measured by
nephelometry (Behring Nephelometer 100 analyzer, Behringwerke, Marburg, Germany) using
rabbit anti-rat albumin antibodies (Cappel, Cochranville, PA, USA). All PA-treated and BB-
induced animals developed albuminuria. The individual nephelometry results are presented in
studies I-V.
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4.3 Isolation of glomeruli of rat kidneys (I, IV, V)
The cortical kidney tissues of each experimental group were pooled together and the
glomeruli were isolated by graded sieving as previously described (164). Briefly, cortical
kidney tissue was finely minced and sieved sequentially through pores of 250, 150 and 105
µm of pore size. The purity of the glomerular preparation obtained was 92-96 % with minor
tubular contamination.
4.4 RNA extraction (I-V)
Cortical kidney or glomerular RNA was isolated either immediately after sacrifice or from
frozen pieces of tissue (50-150 mg) with the single-step acid guanidium thiocyanate-phenol-
chloroform procedure using Trizol® reagent (Life Technologies, Gibco BRL, Paisley,
Scotland) according to manufacturer´s instructions.
4.5 Cloning of rat nephrin cDNA (I)
The library screening for rat nephrin was performed with a rat glomerular cDNA library,
using ZAP Express cDNA Gigapack II Cloning Kit and a PCR-amplified human probe
(Stratagene, La Jolla, CA, USA) as described in detail in study I.
4.6 DNase treatment (II, III, IV)
For the removal of genomic DNA, the RNA was incubated with RNase free DNase I
(Promega, Madison, WI, USA) for 30 min at 37 °C together with human placental RNase
inhibitor (Promega).
4.7 Semiquantitative RT-PCR (I-V)
To compare different mRNA levels of nephrin, its splicing variant forms and other podocyte-
associated molecules in experimental diseases, semiquantitative reverse transcriptase
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polymerase chain reaction (RT-PCR) turned out to be most useful. For this, cDNA was first
synthesized with the Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT)
enzyme (Promega) in the presence of oligo dT15-primer (Boehringer Mannheim) and RNase
inhibitor. cDNAs were diluted from 1:5 to 1:3125 to find the linearity range of PCR reactions.
The amounts of cDNA were equalized according to the β-actin, glyceraldehyde-3-phosphate
dehydrogenase (GAPHD) or cyclophilin levels. Sequence-specific oligonucleotide primers
are presented in Table 3.
PCR amplifications were performed (total volume 25 µl) in the presence of 0.5 µM of each of
the specific oligonucleotide primers, 0.2 mM dNTP (Finnzymes, Espoo, Finland), 10X PCR
Buffer with 15 mM MgCl2 (Perkin-Elmer, Cetus, Norwalk, CT) and 1U AmpliTaq
polymerase (Perkin-Elmer). In the first cycle denaturation was for 3 min at 94 °C and
thereafter for 45 seconds, annealing at 56 °C for 1 minute and extension at 72 °C 45 seconds.
PCR products were electrophoresed in 6% polyacrylamide gels and quantified with the NIH
Image  program as described previously (165).
4.8 Real-time PCR (III)
To confirm the results of semiquantitative RT-PCR, real-time PCR was performed. To detect
the expression levels of nephrin we used a real-time fluorescence based PCR detection
method (TaqMan technology®; PE Applied Biosystems, Foster City, CA, USA) (166, 167).
In this method, a probe, with a reporter dye (FAM) and a quencher dye (TAMRA), attached
to the 5´ and 3´ end, respectively, is used for the detection of PCR-product. During each
extension cycle, the 5´ to 3´ exonuclease activity of Taq DNA polymerase cleaves the reporter
dye from the quencher and a fluorescence signal is emitted. The instrumentation from PE
Applied Biosystems (model 7700) was used for the detection of the fluorescence emitted.
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4.9 Immunofluorescence microscopy (I, II, IV, V)
Kidneys dissected and snap-frozen in liquid nitrogen were embedded in Tissue-Tek®
Compound (Sakura) and cut into cryosections of 3-6 µm and fixed. The fixative used was
dependent on the primary antibody, either 3,5 % paraformaldehyde (PFA, Sigma Chemicals)
for 10 minutes or acetone (Sigma Chemicals) for 10 minutes. The fixations were followed by
repeated rinses in phosphate-buffered saline (PBS: 140 mM NaCl, 2,7 mM KCl, 1,5 mM
KH2PO4, 8,2 mM Na2HPO4, pH 7,4) at room temperature for 15 minutes. Triton X-100 (Fluka
BioChemica, GmbH, Buchs, Switzerland) at 0,1 % in PBS was added to the PFA fixative to
enhance permeabilization. With acetone fixation, no detergent was necessary. To minimize
unspecific binding of the antibodies, the cryosections were incubated in 10 % normal rat
serum (NRS) or 10% fetal calf serum (FCS) at room temperature for 30 minutes followed by
incubation with the primary antibodies diluted in 5-10 % NRS with 0.5% saponin in PBS at
room temperarure for 1 h. The mounting medium consisted of 50 % glycerol in PBS
(Immumount, Sigma). For fluorescence microscopy, an Olympus OX-5O microscope or a
Zeiss Axiophot 2 microscope equipped with appropriate filter systems for FITC and TRITC-
fluorescence was used.
4.10 Immunoelectron microscopy (II, V)
Immunoelectron microscopy was performed essentially by two alternative procedures. In
procedure one, fixation was done for 6 h at 20 °C followed by embedding in Lowicryl K4M
(Chemische Werke LOWI, Waldkraiburg, Germany). Ultrathin sections were blocked with
1% ovalbumin in PBS for 1h, followed by incubation with affinity purified rabbit anti-nephrin
antibodies (50 µg/ml) and a goat anti-rabbit 10-nm gold conjugate (1:50) (Sigma). Sections
were counterstained with lead citrate. For quantitations, the gold particles were counted from
photographs, particularly for slit membrane/ plasmalemmal localization in the models studied
(168). In procedure two, kidneys were perfused with Dulbecco's modified Eagle's medium,
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followed by 4% PFA in 100 mM phosphate buffer, pH 7.4, for 15 min. Kidney cortex
samples were then immersion fixed in 4% PFA for 45 min followed by 8% PFA for 15 min.
Samples were cryoprotected and frozen in liquid nitrogen. Ultrathin cryosections
(approximately 80 nm) were cut on a Leica Ultracut UCT microtome (equipped with a
cryoattachment at -100°C), blocked with 10% FCS in PBS for 30 min, and incubated with
anti-CD2AP antibodies at RT for 2 h. The primary antibodies were detected by incubation
with goat anti-rabbit gold conjugate (5 nM; Sigma) at RT for 1 h. Sections were then stained
with 2% neutral uranyl acetate for 20 min, adsorption-stained with 0.2% uranyl acetate, 0.2%
methyl cellulose, 3.2% polyvinyl alcohol and examined with a JEOL 1200 EX-II electron
microscope (169).
4.11 Western blotting and quantitative immunoblotting (II, IV)
For western blotting the glomeruli were lysed in RIPA buffer (150 mM NaCl, 1% Np-40; 0,5
% sodium deoxycholate; 0,1% sodium dodecyl sulphate (SDS), 50 mM Tris-Cl, pH 8, 0) with
a glass homogenizer and the total protein concentration was measured with BCA Protein
assay kit (Pierce, Rockford, IL). The urine samples were diluted in Laemmli buffer (300
Tris.Cl, 4% SDS, 20% glycerol, 0,05% bromphenolblue). The glomerulus lysates with
adjusted concentrations were diluted 1:1 in Laemmli Buffer containing 1:20 of β-
mercaptoethanol (FlukaChemie, Buchs, Germany) and boiled for 5 minutes. The samples
were run on 8 % SDS-PAGE gels with the Protean Mini-gel electrophoresis facility apparatus
(Bio-Rad Laboratories, Richmond, CA, USA). The proteins were transferred onto 45-micron
nitrocellulose membranes (Amersham LifeScience, Buckinghamshire, UK). The membranes
were blocked with 3 % BSA in PBS overnight at + 4 °C, after which they were incubated with
the respective primary antibodies at room temperature for one hour. This was followed by
washes with 0,2 % Triton X-100-PBS. The peroxidase-conjugated secondary antibodies were
diluted in 0,2 % Triton X-100-PBS to 1: 2000, and were incubated on the membranes at room
temperature for one hour. Thereafter, the filters were washed thoroughly. The peroxidase
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signal was enhanced using the ECL method (Amersham Pharmacia Biotech, Germany) and
the images were developed on FUJI Super RX films (Fuji Photo Film Co, Ltd, Tokyo, Japan).
The developed films were scanned with Biometra Gel Analyzer (BioDocAnalyze, Biometra
Analytik GmbH, Göttingen, Germany) and analyzed by the NIH image analysis program
(National Institutes of Health, Bethesda, MD, USA).
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RESULTS
1. Characterization of the rat nephrin homologue (I)
Cloning of rat nephrin cDNA was essential for the further studies of renal diseases in
experimental rat models. The cloning was carried out using a rat glomerular cDNA library,
commercial cloning kit and a PCR-amplified probe hybridised with human nephrin. To
retrieve the full-length cDNA, additional library screening was performed according to the
mouse nephrin cDNA sequence with 5´ rat cDNA probe.
Rat homologue of nephrin showed 82% identity to human nephrin at cDNA level. In the
translation into amino acid sequence the identity level was 90%, 99% and 83% in the
extracellular, transmembrane and intracellular domains, respectively. The predicted amino
acid sequence was 89% identical with the human sequence and its estimated protein mass was
134,7kDa. The proposed number of cysteine residues and predicted degree of glycosylation
was almost identical to those of human.
In addition to the full-length nephrin cDNA, library screening yielded two splice variants,
alpha and beta. The sequences of the cDNAs obtained were confirmed by sequencing with
specific primers (Table 3.). The RT-PCR analysis revealed five amplified products. In
addition to the full-length mRNA, α  and β forms, two additional products; gamma (γ) and
delta (δ) were detected. Upon verification the γ and δ forms were shown not to be in an open
reading frame.
2. Nephrin mRNA levels in acute PA nephrosis (I, II, III)
To detect the expression level of rat full-length nephrin mRNA we used semiquantitative RT-
PCR, as Northern blotting was not sensitive enough. Already after three days (early phase
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changes) in all PA treated groups, nehprin mRNA levels showed a 40% downregulation
(P=0.037), and after ten days (late phase changes) an 80% downregulation (P=0.027), as
compared with the respective levels in the controls (Figure 2, study II). The verification of the
semiquantitative RT-PCR was performed with real-time PCR. The results were compatible
(Table 1, study III). The treatment with HgCl2 led to a similar pattern with a rapid decrease of
nephrin mRNA level at day 3, whereas pretreatment with probucol resulted in non-significant
1.4- and 1.35-fold increases at days 3 and 10, respectively (Figure 3, study II.). In the group
combining PAN and HgCl2 treatments, an even more pronounced drop in the nephrin mRNA
level was observed at day 3.
Semiquantitation of mRNA with primers designed according to the α-nephrin sequence in
PA-treated rats showed a significant reduction when compared with the control levels (Figure.
1 and 2, study III). The significant decrease was 40 % and 70 % on days 3 and 10 days,
respectively. A similar pattern was seen in the full-length nephrin mRNA levels.
3. Alterations in the expression of nephrin protein in acute nephrosis (I, II)
The immunohistochemical stainings were performed with anti-peptide antibodies against the
intracellular domain of nephrin. Nephrin-specific coarse linear reactivity was detected in
normal glomeruli (Fig.1B, study I and Fig.4A, study II). In the PA-treated group the intensity
was diminished along in the course of nephrosis, and the least intense and irregular signal was
observed at day 10. Less marked changes in reactivity were also found for HgCl2 treated
kidneys (Figure 4 and Table 2, study II)
The quantitative immunoblotting results complemented the semiquantitative IF studies on
nephrin. The protein expression was decreased 40% at day 3 and was more than 70% at day
10.
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The confirmation of the expression and localization of nephrin in normal and PA glomeruli
was performed by immunoelectron microscopy. Anti-intra-nephrin antibody with gold label
bound specifically to SD area, but a few cold particles were also found at the apical
membrane (Figure 5, study II). The counted gold particles revealed changes in localization of
nephrin antigen after PA treatment. Relative distribution was 87% at the apical surface and
13% at SD after PA while in controls, the ratios were 27% and 73% at the apical surface and
SD, respectively (Table 3, study II).
5. Screening of urinary nephrin after PA-treatment (III)
The urine samples of PA-treated rats were screened by immunoblotting. By using nephrin
recognizing polyclonal antibodies, we found a reactive protein with a size of 166-172 kDa at
day 6 when the first peak of proteinuria is detected and at day 10 during the highest peak of
proteinuria, while in early phases no such signal in the urine could be detected. Since the
detected protein appeared to be smaller than that found in glomeruli, it was proposed to be the
α-splicing form.
6. Scanning of gene expression levels of other podocyte-associated molecules
in PA nephrosis (IV, V)
The relative amount of mRNA of selected podocyte markers were analysed by
semiquantitative RT-PCR. The specific primers designed according to the α-dystroglycan,
β1-integrin, P-cadherin, α-actinin-4, podocin and CD2AP sequences are listed in Table 2. The
most apparent changes were in α-actinin-4 and podocin mRNA levels. After 3 days of PA
treatment, α-actinin-4 mRNA level was elevated 2-fold and continued up-regulated
approximately 1.6-fold at day 10 compared to the controls (Figure 2, study IV). Podocin
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expression was up-regulated 1.6-fold both days 3 and 10. Gene expression of α-dystroglycan,
β1-integrin and P-cadherin was not considerably altered after PA-treatment.
Administration of PAN resulted in a 50% down-regulation of CD2AP already 3 days after the
induction of nephrosis, and on day 10, CD2AP mRNA was down-regulated being 40% of that
in the controls (Figure 1, study V).
7. Effect of PA treatment on relative protein content of other podocyte-
associated molecules (IV, V)
Quantitative Western blotting achieved by protein concentration determination prior to
blotting enabled more accurate analysis of particular proteins in PA nephrosis. The
quantitations are presented in figure 3 in study IV. The most evident up-regulation was that of
β1-integrin. The 2-fold rise in protein amount was observed both at early and later phases of
the disease. The level of podocin dropped to 50 % in 3 days and continued to fall, being only
10% of control levels after 10 days, which turned out to be similar to that of nephrin. β-
catenin was down-regulated about 50 % at day 3 but recovered back to control levels at day
10. No considerable changes were seen in α-actinin-4 or α-dystroglycan.
Immunohistochemical analysis supported the results achieved by quantitative Western
blotting. Podocin specific reactivity was less intensive in 10-day PAN rat kidney section
when compared to control (Figure 5, study IV). β1 integrin staining was more intense at later
phase sections than in controls.
In the control rat glomerulus, CD2AP staining was intense along the basal poles of the
podocytes (Figure 2A, study V). In the acute PA rat model of nephrosis this localization
changed. In the 10-day samples of the PA group, the immunoreactivity for CD2AP was
reduced as compared to the normal kidney. In PAN (not shown) and PAN together with
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mercuric chloride (Figure 2D, study V) models, some patchy staining was observed in
addition to a weak, diffuse immunoreactivity seen all over the glomeruli. In the samples
treated with mercuric chloride alone, CD2AP signal was very weak and diffuse (not shown).
Double immunofluorescence analysis of normal rat kidneys, using a rabbit CD2AP antibody
and a mouse nephrin antibody directed against the extracellular domain of nephrin, revealed
basal staining of the glomerular epithelial cells with both antibodies (Figure 3A-C, study V).
CD2AP staining was, however, more continuous as compared to the patchy staining of
nephrin. In acute PA nephrosis and its modifications (Figure 3J-L, study V), the glomerular
signals for both CD2AP (Figure 3J, study V) and nephrin (Figure 3K, study V) were distinctly
reduced. Both staining patterns included occasional patchy, partially overlapping signals of
more distinct fluorescence.
Immunoelectron microscopy regularly revealed CD2AP-specific labeling in the podocyte foot
processes of control glomeruli (Figure 4A-C, study V). Gold particles were frequently seen in
the vicinity of the slit diaphragm areas but also elsewhere in the foot process cytoplasm.
In 3-day PAN samples (Figure 4D-E, study V), representing early developing nephrosis, the
podocytes started to show loss of foot processes, apical displacement of slit diaphragms
(Figure 4E, V), and formation of occludin-type junctions (Figure 4E, study V). The intensity
of the CD2AP signal in the modified foot processes appeared similar to that in the controls.
Gold particles were seen both close to the basal cell membrane and elsewhere in the
cytoplasm. Labeling was often, but not constantly, seen in the vicinity of occludin-type
junctions (Figure 4E, study V) and preserved slit diaphragms.
In the 10-day PA nephrosis samples (Figure 4F-G, study V), the podocytes showed fully
developed effacement including practically complete loss of foot processes and SD, presence
of occludin junctions, and frequent detachment of podocytes from GBM. The intensity of the
CD2AP signal in podocytes was dramatically diminished. The effaced foot processes almost
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completely lacked gold particles, and only few particles were found elsewhere in the
cytoplasm (Figure 4F, Study V). However, in accordance with the immunofluorescence
results, some CD2AP signal was detected in the effaced foot processes on rare occasions
(Figure 4G, study V). The remaining label for CD2AP was regularly found in close
association with the disorganized actin cytoskeleton, and occasionally the gold particles were
associated with discernible microfilaments (Figure 4G, study V).
8. Nephrin and CD2AP in Heymann nephritis (II, V)
After 12 weeks of BB antigen induction in HN semiquantitative RT-PCR results with nephrin
primers did not show any significant changes in mRNA expression levels.
In IF the nephrin protein showed only slight changes in HN when compared to controls
(Figure 4B and table 2, study II)
The distribution of gold particles was detected by immuno EM with nephrin antibody. The
results showed equal distribution with controls (Table 3, study II)
The more significant changes were seen in the expression of the CD2AP protein. In IF the
localization of CD2AP changed in HN. The signal for CD2AP in glomeruli was strong, but a
large fraction of the protein appeared in a punctate fashion (Figure 2B, study V). In HN with
L-NAME, a nitric oxide synthase inhibitor, however, the staining pattern was totally different:
CD2AP immunoreactivity decorated the cells aligning the dilated glomerular urinary spaces
as clear lines (Figure 2C, study V).
In double IF analysis the level of glomerular signal for CD2AP in HN glomeruli was similar
to that in controls. The staining pattern of CD2AP included punctate aggregates (Figure 3D,
study V), which often located in close proximity to similar aggregates of the nephrin signal
(Figure 3E, study V). If the chronic nephrosis was induced with the combination of BB
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antigen and L-NAME (Figure 3G-I, study V), the glomerular distribution of CD2AP was
largely linear (Figure 3G, study V), whereas the expression and organization of nephrin were
more severely disturbed (Figure 3H, study V).
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DISCUSSION
This thesis collects together data obtained by studying the regulation of podocyte-associated
molecules in proteinuric disease models in rats. Studies with animal models have been
instrumental in providing data about the pathophysiology of proteinuria and rat models have
been shown to be particularly useful in the study of renal diseases and have been used
routinely from the mid 1950´s. The animal homologues of human molecules are essential for
utilizing experimental models effectively.
1. Expression and localization of nephrin in tissues (I)
The human NPHS1 gene, located in chromosomal area 19q13.1, encodes a transmembrane
protein nephrin and, when mutated it causes CNF (3). Our characterization of the rat nephrin
cDNA showed 82% identity with human nephrin cDNA and was shown to contain an open
reading frame of 3705 bp. Cloning of the rat nephrin homologue also revealed distinct mRNA
splicing: α−  and β-variants. The alternatively spliced α-form of nephrin lacks the whole
transmembrane area and part of the intracellular domain. The same variant is found in human
nephrin, with an exact exclusion of the exon 24 encoding only the transmembrane domain
(109). The expression of alternatively spliced nephrin and their possible significance in
proteinuric conditions are discussed below. Additionally, RT-PCR analysis revealed rat
nephrin mRNA expression in the spleen.
Comparison of the translated amino acid sequences of human and rat nephrin showed 89%
homology over the extracellular, intracellular, and transmembrane domains. Translation
revealed highly conserved cysteine residues, signal sequences and ten putative N-
glycosylation sites. This proves that the structure of rat nephrin is closely related to that of the
respective human molecule (170). The estimated molecular mass of rat nephrin protein is 134
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kDa, however, in immunoblotting, a double band of approximately 185-200 kDa was seen.
This can be explained by two different transcripts and post-translational modifications (170).
Two other groups have also published the characterization of rat nephrin and confirmed the
findings of the observed homology with human nephrin (170, 171).
It is of interest that we have cloned the mouse nephrin (110), a finding that was later
confirmed by Putaala et al. (171). The isolated mouse nephrin RNA was the size of 4.1 kb and
was predicted to contain 1242 amino acids. Cloning of mouse nephrin revealed 93 %
homology compared to rat nephrin, and 82 % to human. The main difference between human
and mouse nephrin cDNA is that mouse nephrin contains 30 exons instead of the 29 exons in
human nephrin (171).
In the glomerulus of normal kidneys nephrin is primarily localized in the slit diaphragm (109-
111, 171) In addition, nephrin is always found in the apical membrane of the foot processes of
podocytes (109). First studies on the nephrin protein suggested that it is kidney-specific (3)
but it has subsequently been found elsewhere, too. Palmén et al. reported both nephrin mRNA
and protein expression in the insulin producing ß-cells in the adult human pancreas (115).
Putaala et al. reported mRNA expression of nephrin in the mouse embryo hindbrain, spinal
cord and cerebellar radial glial cells (116, 171). Furthermore, nephrin has also been reported
in the Sertoli cells of testis (117). In addition to these findings we have found nephrin
expression in rat lymphoid cells and tissues at both mRNA and protein levels (Åström et al.,
unpublished). Possible functions for nephrin judged by its structure and expression pattern as
well as interactions with other glomerular molecules are discussed below.
2. Function of nephrin in SD
Localization of nephrin in SD suggests that it is a major structural component involved in the
composition of the ultrafiltration barrier of the glomerulus. In addition, due to its molecular
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structure with the repetitive Ig-like domains extending outwards from the plasma membrane
and expression in the course of kidney development, nephrin is likely to participate in cell
adhesion (3, 112) and signalling (113, 114). It has been proposed that nephrin, according to its
structure, binds to another nephrin molecule of the adjacent podocyte in a homophilic fashion
(111, 172). However, this proposal has not been verified.
Nephrin has been shown to be a crucial element in the development of glomerular podocytes
in human (112), rat (170) and mouse (116). During normal glomerulogenesis, nephrin mRNA
appears first in the late S-shaped bodies of the cells in vascular clefts (112). In addition to
development of glomeruli, in situ studies on whole mouse embryos revealed nephrin mRNA
expression in the hindbrain and spinal cord. Immunohistochemical analysis of nephrin protein
implies nephrin also to have a role in brain, at least certain regions. However, mice with
inactivated NPHS1 gene did not show any morphological changes in the cerebellum (116,
171).
Findings from the pancreatic and lymphoid cells suggest that nephrin not only participates in
the maintenance of SD in the glomerular filtration barrier, but may also play a role in islet cell
function in the pancreas (115), and perhaps in the antigen presentation in the immunologic
system (Åström et al., unpublished).
Association and co-localization studies with nephrin and other podocyte molecules have
shown that nephrin interacts with many other proteins. It has been shown that nephrin
interacts with CD2AP (4, 120), originally cloned from T cells. CD2AP is also expressed in
podocytes, especially in SD and is crucial for normal kidney function (4). The interaction
with nephrin occurs at the cytoplasmic carboxy-terminal domain of CD2AP (121). It has been
suggested that nephrin is anchored to the cytoskeleton via this domain (121). Accordingly,
nephrin/CD2AP complex provides part of the structural integrity of SD.
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Podocin encoded by NPHS2 is an integral membrane protein expressed in podocytes.
Mutation in NPHS2 causes autosomal recessive steroid-resistant nephrotic syndrome (5).
Similarly to nephrin, podocin appears to accumulate in oligomeric forms in lipid rafts (113,
125). Oligomerized podocin then interacts with nephrin and CD2AP and is needed for the
functional assembly of SD (125). Huber et al. showed that nephrin with its several potential
tyrosine phosphorylation sites is also a signalling molecule. The interaction of its cytoplasmic
tail with podocin enhances signalling of nephrin (114).
3. Rat nephrin is characteristically regulated in renal diseases (II)
The identification of NPHS1, mutated in CNF, opened a new way to approach molecular
mechanisms of glomerular ultrafiltration. Using an experimental PA nephrosis model to study
the alterations of rat nephrin, we found a 60% reduction in the early phase and a remarkable
80 % down-regulation of nephrin mRNA in the late phase of PA induction. This finding
shows that nephrin mRNA is regulated before the highest peak of proteinuria. On the EM
level the distribution of nephrin protein was also altered in PA nephrosis model: nephrin
escaped from the slit area towards the apical membrane of foot processes after PA treatment.
Another group subsequently also reported reduced on expression of nephrin mRNA in PA
nephrosis (170). They found a 51.2% reduction in mRNA already after two hours but in IF
they did not see any changes. After 9 days of PA induction the intensity of nephrin protein
was significantly decreased in IF. These results get support from findings in human kidney
diseases. For instance, in human acquired nephrotic syndromes nephrin mRNA is down-
regulated and protein redistributed (173-175). In the present study, after HgCl2, induction over
40% drop in expression of nephrin mRNA level was seen even in the absence of significant
proteinuria. This early phase response can be due to lipid peroxidation seen both in HgCl2 and
PA induction.
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In our model of HN, no significant changes in the expression of nephrin were observed. This
can be due to the late time of collection of samples, after 12 weeks of induction. However,
Benigni et al., as well as Yuan et al. reported reduction in nephrin expression in passive HN
(176, 177). Thus, more detailed study of nephrin expression in chronic HN at different time
points would be informative.
Several other studies also present evidence on involvement of nephrin in experimental renal
diseases. Administration of a monoclonal antibody, 5-1-6 that binds to SD, results in transient
massive proteinuria in rat (178). The antibody is postulated to recognize the extracellular
domain of rat nephrin (179). Furthermore, expression of the antigen located in SD changes in
proteinuric diseases (180) and in 5-1-6 nephropathy nephrin expressions is decreased (170,
181).
In the streptozotocin model of experimental diabetic nephropathy, modulation of nephrin
mRNA and protein expression is seen. At early time points of diabetic nephropathy rats, i.e.
four to eight weeks, nephrin mRNA is up-regulated and simultaneously free nephrin leaks
into urine (182). In another study, in spontaneously hypertensive streptozotocin diabetic rats,
nephrin mRNA expression was down-regulated and immunohistochemistry for nephrin
showed depletion after 18 to 24 weeks of induction (183). These results suggest that nephrin
is crucial for the permselectivity of glomerulus and is regulated in proteinuric conditions.
4. Splicing variant α-nephrin mRNA in proteinuric condition (I, II)
Alternative splicing produces a variety of protein isoforms in vivo. It can occur tissue-
specifically, at different developmental stages, and disease conditions, but little is known
about the regulatory mechanisms of alternative splicing.
We have found that both in man (109) and in the rat nephrin is characteristically spliced. In
addition to the full-length nephrin mRNA, we described the splicing variants α and β in the
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rat. α-nephrin mRNA lacks the exon encoding transmembrane domain and most probably
produces a truncated and soluble form of the protein. The detailed study of α-nephrin mRNA
in PAN showed similar reduction as full-length mRNA. Simultaneously, we found nephrin
protein from PAN urine samples during the first and second peaks of proteinuria. Whether the
nephrin found in the urine is the product of the α-variant mRNA that produces a soluble form
of nephrin, or due to changes in glycosylation remains to be studied in detail. The α-form
may possibly act as a regulator of full-length nephrin in diseased kidneys. An example of
such regulation is the soluble interleukin-6 receptor, which has been shown to function as an
antagonist, blocking or reducing the potency of the ligand.  The soluble forms of receptors
can show even higher affinity to ligands than membrane-bound isoforms (184). To determine
the use of soluble nephrin as a predictive marker in proteinuric conditions is still under study.
5. Molecular architecture of podocytes (IV, V)
The plasma membrane of the foot processes of podocytes can be divided into three domains:
basal domain, apical domain and slit diaphragm that is in between those two domains (Figure
2). This architecture is maintained by specific arrangement of podocyte molecules (108).
Well-organized cytoskeleton with its associated proteins and interaction between proteins
located in different domains of the podocyte cell membrane maintain the specific morphology
of foot processes. The PA model of acute nephrosis was chosen for the analysis of alterations
in the content of structural and functional molecules. Previously, only few reports have been
published concerning the adjustment of podocyte-associated molecules in PA nephrosis (130,
185).
Here, the results indicate that the podocyte-associated molecules, located in different domains
of the cell, are regulated distinctly but these changes may take place in a well-coordinated
way. The defect in the molecular composition of slit diaphragm is seen in proteinuric
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conditions. Besides nephrin, many molecules have been found to localize in SD. They include
podocin (5), CD2AP (121), FAT (186), α, β, γ -catenins, P-cadherin, and ZO-1 (91).
The importance of nephrin in nephrotic disorders has been discussed above. On the other
hand, podocin might also have an important function. Podocin links plasmamembrane
proteins to the cytoskeleton (5). Additionally, podocin has been suggested to enhance nephrin
signal transduction (114). In our study, the most significant changes obtained were in the
reduction of podocin and nephrin proteins. PA-treatment increased the podocin mRNA level
1.6-fold, but at the same time the protein level decreased to 50% and 10% at days 3 and 10,
respectively. Thus, the podocin protein levels followed patterns seen in the regulation of
nephrin protein
CD2AP, another essential molecule for the normal kidney function, is expressed in podocytes,
especially in SD (4). Accordingly, CD2AP-deficient mice develop kidney disease resembling
nephrotic syndrome. CD2AP interacts with CD2 (118), polycystin-2 (119), nephrin (121) and
recently it has been shown to interact with actin (Lehtonen, in press). In our study CD2AP
showed alterations at mRNA level similar to its interacting partner nephrin. The IF studies
paralleled well the mRNA semiquantitations; when the intensity of CD2AP staining was
decreased also the mRNA expression pattern was reduced. Additionally, in immuno EM
obliterated foot processes were obvious in later phases of the nephrosis.
Receptors for extracellular matrix proteins in the basal domain of foot processes, including
dystroglycans and integrins, have an essential role in podocyte cell-matrix adhesion (135,
187). α3β1 integrin is the main form of integrins expressed in podocytes, and it participates in
stabilizing podocyte foot processes. Our findings showed a remarkable 2-fold increase in β1
integrin at protein level after PA treatment, both in early and later phase.
α-actinin is a member of cytoskeleton-binding proteins and associates with various other
proteins, linking for example the cytoplasmic domain of β1 integrin to the cytoskeleton (129).
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The isoform α-actinin-4, encoded by ATCN4, is expressed in podocytes, especially in foot
processes (127). Our results did not reveal any changes in α-actinin-4 protein quantities, but
its mRNA level raised 2-fold at the early phase of PA nephrosis. Smoyer et al. reported
changes in α-actinin before day 3 in PA nephrosis but did not see alterations thereafter (130).
By adapting rapidly to a direct impact imposed upon the podocyte, α-actinin-4 plays a
significant role in the maintance of a well-organised cytoskeleton.
Together these findings suggest that podocyte proteins are regulated differentially in
nephrotic glomeruli according to the structure and location in the plasma membrane.
Especially, certain SD molecules, such as nephrin, podocin and CD2AP, are regulated before
the highest peak of proteinuria. These central molecules serve as an integrated composition of
glomerular filtration barrier and disturbances in their expression eventually leads to
proteinuria.
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SUMMARY
The slit diaphragm (SD) that works as a final sieve of ultrafiltration is a complex assembly of
many molecules. This assembly maintains the filtration barrier whose perturbation manifests
as proteinuria. The mechanisms for this remain still largely unknown. Experimental animal
models are extensively used to provide information concerning proteinuric diseases. The
discoveries of nephrin and findings thereafter have pointed a new direction in studying the
composition of the filtration machinery.
This thesis combines data that have been acquired using the experimental kidney disease
models of the rat focusing on the regulation of expression of podocyte-associated molecules.
First, it can be concluded that PA nephrosis is suitable for analyzing acute glomerular injury
and molecular mechanisms of ultrafiltration within the kidney. Second, a clear correlation
between the regulation of key molecules in SD, such as nephrin, podocin and CD2AP, and the
manifestation of proteinuria are observed. Alterations of these proteins were seen already
before the peak of proteinuria in the experimental acute model of nephrosis.
Understanding of the role of alternative splicing leading to multiple isoforms of expressed
proteins is greatly expanding. Third conclusion from the present series of studies is that
nephrin is characteriscally spliced in the rat. The alternatively spliced nephrin mRNA, α
nephrin yields proposedly a truncated and soluble form of nephrin. It is possible that α-
nephrin has a controlling role in the pathogenesis of proteinuria. Due to similar splicing
characteristics in human, soluble nephrin may be valuable as a prognostic indicator even
before the disease is clinically evident.
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